公司概覽
業務類別 Biotechnology
業務概覽 Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
公司地址 12390 El Camino Real, San Diego, CA, USA, 92130
電話號碼 +1 858 794-8889
傳真號碼 +1 858 704-8311
公司網頁 https://www.halozyme.com
員工數量 423
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Ms. Cortney Caudill Senior Vice President and Chief Operating Officer -- 17/02/2026
Dr. Helen I. Torley, M.R.C.P.,MB.Ch.B. Director, President and Chief Executive Officer 美元 960.00K 17/02/2026
Mr. Mark Snyder Senior Vice President, General Counsel, Chief Compliance Officer and Secretary 美元 579.00K 17/02/2026
Ms. Nicole LaBrosse Senior Vice President, Chief Financial Officer and Principal Accounting Officer 美元 568.19K 17/02/2026
 
董事會成員
董事會 職務 更新日期
Mr. James Lang Director 17/02/2026
Mr. Jeffrey W. Henderson Chairman of the Board 17/02/2026
Dr. Helen I. Torley, M.R.C.P.,MB.Ch.B. Director, President and Chief Executive Officer 17/02/2026
Mr. Matthew L. Posard Independent Director 17/02/2026
Ms. Bernadette M. Connaughton Independent Director 17/02/2026
Ms. Barbara G. Duncan Independent Director 17/02/2026
Ms. Moni Miyashita Independent Director 17/02/2026
Dr. Mahesh Krishnan, M.B.A. Independent Director 17/02/2026
 
所屬ETF (更新日期: 07/03/2026 04:25)
代號 名稱 佔比% 持有日期
IBBQInvesco Nasdaq Biotechnology ETF0.01%27/02/2026
TILTFlexShares Mstar US Mkt Factors Tilt ETF0.01%27/02/2026
BFORBarron's 400 ETF0.01%28/02/2026
SMIZZacks Small/Mid Cap ETF0.01%27/02/2026
GQQQAstoria US Quality Growth Kings ETF0.005%27/02/2026
AVMCAvantis U.S. Mid Cap Equity ETF0.005%28/02/2026
BIBProShares Ultra Nasdaq Biotechnology0.005%27/02/2026
ISCBiShares Morningstar Small-Cap ETF0.005%28/02/2026
IYYiShares Dow Jones US ETF0.005%28/02/2026
MSSMMorgan Stanley Pathway Sm-Md Cp Eq ETF0.004%28/02/2026
MMSCFirst Trust Multi-Manager Sm Cp Opps ETF0.004%26/02/2026
MSLCMorgan Stanley Pathway Large Cap Eq ETF0.004%28/02/2026
FSGSFirst Trust SMID Growth Strength ETF0.004%26/02/2026
AVLCAvantis U.S. Large Cap Equity ETF0.003%28/02/2026
GUSAGoldman Sachs MarketBeta US 1000 Eq ETF0.003%27/02/2026
MVVProShares Ultra MidCap4000.003%27/02/2026
AVSUAvantis Responsible US Equity ETF0.003%28/02/2026
FTXHFirst Trust Nasdaq Pharmaceuticals ETF0.003%26/02/2026
VSLUApplied Finance Valuation LgCp ETF0.003%27/02/2026
NDOWAnydrus Advantage ETF0.003%27/02/2026
  1    2    3    4    5   6    7    8    9    10    11  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.